Benjamin Goldstein
Internal Medicine · Saint Louis, MONPI 1811919228
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 338 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,813 and has fallen 95.2% since, to $86 in 2024. Among internal medicine clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 338 payments — averaging $15.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$758
- Lilly USA, LLC$732
- Novo Nordisk$652
- Pfizer$367
- E.r. Squibb & Sons, L.L.C.$306
- Biohaven Pharmaceutical Holding Company Ltd.$232
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,079100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 42 | $758 |
| Lilly USA, LLC | 51 | $732 |
| Novo Nordisk | 45 | $652 |
| Pfizer | 25 | $367 |
| E.r. Squibb & Sons, L.L.C. | 20 | $306 |
| Biohaven Pharmaceutical Holding Company Ltd. | 18 | $232 |
| Johnson & Johnson | 14 | $221 |
| Amarin Pharma, Inc. | 15 | $186 |
| Eisai Inc. | 13 | $179 |
| Merck | 11 | $165 |
| AstraZeneca | 10 | $130 |
| Biohaven Pharmaceuticals, Inc. | 7 | $125 |
| Amgen | 7 | $121 |
| Abbott | 7 | $116 |
| Sanofi-aventis U.S. LLC | 7 | $102 |
| Dexcom, Inc. | 7 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $82 |
| GSK | 6 | $78 |
| Sanofi Pasteur Inc. | 4 | $56 |
| Vanda Pharmaceuticals Inc. | 3 | $50 |
| Novartis | 3 | $36 |
| GE HealthCare | 1 | $31 |
| Shield Therapeutics Inc | 2 | $31 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Alkermes, Inc. | 1 | $25 |
| Lundbeck LLC | 1 | $22 |
| Bayer | 1 | $20 |
| Bausch Health US, LLC | 1 | $20 |
| Dynavax Technologies Corporation | 1 | $18 |
| Optinose US, Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Nalpropion Pharmaceuticals LLC | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $13 |
How this compares
$5,097 in reported general payments places this provider in the 90th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Saint Louis
- Vinay KamatSaint Louis$191K
- David PrelutskySaint Louis$182K
- Tracy NorfleetSaint Louis$132K
- Paul OlivoSaint Louis$98K
- William SummersSaint Louis$93K
- Mark ScheperleSaint Louis$89K
- Shiyang ZhangSaint Louis$45K
- Bernard McGuireSaint Louis$37K
- Daniel GaitanSaint Louis$34K
- Nathan FarkasSaint Louis$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.